Too many middlemen disconnects you from patients.

See How Close
Lost in Transition Telephones
Lost in Transition

Treating rare disease shouldn’t be like a bad game of telephone, with each step generating chaos and confusion. Patient adherence suffers, quality of care diminishes, manufacturers miss out on vital feedback and cost goes up. But imagine if you you could cut past all that. We did.

Learn More

DOHMEN NEWS

Learn what's happening in the world of Dohmen and our clients
May 17, 2017

Dohmen welcomes Todd Sparlin, Vice President, Client Finance, DLSS

Dohmen has appointed Todd Sparlin as its new Vice President of Client Finance for Dohmen Life Science Services. With more than 20 years of experience in the finance and healthcare industries, he focuses on implementing financial strategies to increase clients’ profitability, improve cash flow and optimize investments.
learn more
May 10, 2017

Dohmen's high-touch patient support model featured in PharmaVOICE

A recent issue of PharmaVOICE highlights how the integrated model for rare disease patient support helps improve therapy adherence and build better patient relationships.
learn more
May 08, 2017

Dohmen announces new Vice President, Contracting and Payer Access, DLSS

Dohmen has appointed Brian Davis as its new Vice President of Contracting and Payer Access for orphan drug manufacturers for Dohmen Life Science Services. With 15 years of experience in managed care contracting, he has held roles leading both contracting and compliance departments. He’s also a pharmacist and has an extensive background in public policy and professional regulation.
learn more
March 27, 2017

Dohmen releases new white paper on improved outsourcing model for orphan drug manufacturers

The $114 billion orphan drug industry is traditionally served by a multi-channel model of disparate service providers. Each claims expertise in a specific niche of services, yet therapy adherence for rare disease patients is just over 58 percent. The Dohmen Life Science Services white paper explores an integrated outsourcing model that’s driving better adherence, supporting healthier outcomes and helping orphan drug manufacturers continuously improve their patient program with lower cost and less risk. Industry experts and patient advocates weigh in on why business process outsourcing must evolve.
learn more
February 27, 2017

Dohmen unveils infographic recognizing importance of Rare Disease Day 2017

This week Dohmen Life Science Services joins millions of people in recognition of Rare Disease Day on February 28 – a worldwide effort to raise awareness for the patients and caregivers impacted by rare disease every day.
learn more
December 20, 2016

Dohmen’s Wendy White named Global Genes Chairman of the Board

Global Genes, one of the world’s leading nonprofit rare disease patient advocacy organizations, recently named Wendy White, Dohmen Life Science Services (DLSS) Senior Vice President, Rare Disease, as the Chairman of the Board.
learn more
November 22, 2016

Dohmen sponsors annual HBA conference helping transform women leadership in healthcare

Dohmen Life Science Services recently joined more than 900 industry leaders at the annual Healthcare Businesswomen’s Association (HBA) conference. As one of three Diamond sponsors, DLSS helped shine light on the importance of women leaders in healthcare.
learn more
November 17, 2016

Twelve months & counting: Are you ready for DSCSA?

Upcoming Drug Supply Chain Security Act (DSCSA) legislation outlines critical steps to identify and trace certain prescription drugs as they are distributed in the United States. The new requirements impact manufacturers, repackagers, wholesalers, dispensers and third-party logistics providers to varying degrees. Pat McGinn, DLSS expert for DSCSA compliance, shares these top 5 tips for manufacturer readiness.
learn more
Next >